Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSR411298 dose-finding study in elderly patients with major depressive disorder
2008-001718-26Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SSR411298 in major depressive disorder (MDD) (5 arms), sponsored by Sanofi. Primary endpoint: Change from baseline to Day 56 in 17-item Hamilton Depression Rating Scale. Started Oct 2008; status: completed.
02
Drugs
SSR411298
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2008-001718-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001718-26.